Ausgabe 7/2019
Inhalt (26 Artikel)
18F-FDG uptake of brown fat and cancer: casualty or causality?
Nicolò Gennaro, Giovanna Pepe, Lidija Antunovic
Breaking an unhelpful circle, where innovation and regularia delay clinical practice for patient benefit
Peter Ell, Ignasi Carrio, Arturo Chiti
Endorsement of International Consensus Radiochemistry Nomenclature Guidelines
Philip Elsinga, Angelika Bischof Delaloye, Arturo Chiti, Stefaan Vandenberghe, Francesco Giammarile, Ignasi Carrio
EANM Focus 1: one small step for two men, one giant leap for a specialty
Stefano Fanti, Wim J. G. Oyen
Time for new imaging and therapeutic approaches in cardiac amyloidosis
Riemer H. J. A. Slart, Andor W. J. M. Glaudemans, Walter Noordzij, Johan Bijzet, Bouke P. C. Hazenberg, Hans L. A. Nienhuis
Detection of cardiac amyloidosis with 18F-Florbetaben-PET/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy
Malte Kircher, Sandra Ihne, Joachim Brumberg, Caroline Morbach, Stefan Knop, K. Martin Kortüm, Stefan Störk, Andreas K. Buck, Theresa Reiter, Wolfgang R. Bauer, Constantin Lapa
Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI
Qaid Ahmed Shagera, Gi Jeong Cheon, Youngil Koh, Min Young Yoo, Keon Wook Kang, Dong Soo Lee, E. Edmund Kim, Sung-Soo Yoon, June-Key Chung
TSH suppression aggravates arterial inflammation — an 18F-FDG PET study in thyroid carcinoma patients
Ellen Boswijk, Karin J. C. Sanders, Evie P. M. Broeders, Marlies de Ligt, Guy H. E. J. Vijgen, Bas Havekes, Alma M. A. Mingels, Roel Wierts, Wouter D. van Marken Lichtenbelt, Patrick Schrauwen, Felix M. Mottaghy, Joachim E. Wildberger, Jan Bucerius
Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial
Maja Guberina, Wilfried Eberhardt, Martin Stuschke, Thomas Gauler, Clemens Aigner, Martin Schuler, Georgios Stamatis, Dirk Theegarten, Walter Jentzen, Ken Herrmann, Christoph Pöttgen
Radiotherapy boost in patients with hypoxic lesions identified by 18F-FMISO PET/CT in non-small-cell lung carcinoma: can we expect a better survival outcome without toxicity? [RTEP5 long-term follow-up]
Pierre Vera, Sorina-Dana Mihailescu, Justine Lequesne, Romain Modzelewski, Pierre Bohn, Sébastien Hapdey, Louis-Ferdinand Pépin, Bernard Dubray, Philippe Chaumet-Riffaud, Pierre Decazes, Sébastien Thureau
Development and validation of the PET-CT score for diagnosis of malignant pleural effusion
Min-Fu Yang, Zhao-Hui Tong, Zhen Wang, Ying-Yi Zhang, Li-Li Xu, Xiao-Juan Wang, Wan Li, Xiu-Zhi Wu, Wen Wang, Yu-Hui Zhang, Tao Jiang, Huan-Zhong Shi
PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy
Lidija Antunovic, Rita De Sanctis, Luca Cozzi, Margarita Kirienko, Andrea Sagona, Rosalba Torrisi, Corrado Tinterri, Armando Santoro, Arturo Chiti, Renata Zelic, Martina Sollini
Exploratory radiomic features from integrated 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging are associated with contemporaneous metastases in oesophageal/gastroesophageal cancer
Serena Baiocco, Bert-Ram Sah, Andrew Mallia, Christian Kelly-Morland, Radhouene Neji, J. James Stirling, Sami Jeljeli, Alessandro Bevilacqua, Gary J. R. Cook, Vicky Goh
Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma
Frank Hofheinz, Yimin Li, Ingo G. Steffen, Qin Lin, Chen Lili, Wu Hua, Jörg van den Hoff, Sebastian Zschaeck
Perioperative PET/CT lymphoscintigraphy and fluorescent real-time imaging for sentinel lymph node mapping in early staged colon cancer
M. Ankersmit, O. S. Hoekstra, A. van Lingen, E. Bloemena, M. A. J. M. Jacobs, D. J. Vugts, H. J. Bonjer, G. A. M. S. van Dongen, W. J. H. J. Meijerink
Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization
Kostas Delaunay, Julien Edeline, Yan Rolland, Nicolas Lepareur, Sophie Laffont, Xavier Palard, Christelle Bouvry, Samuel Le Sourd, Marc Pracht, Valérie Ardisson, Nicolas Noiret, Éric Bellissant, Etienne Garin
18F-FPPRGD2 PET/CT in patients with metastatic renal cell cancer
Akira Toriihara, Heying Duan, Holly M. Thompson, Sonya Park, Negin Hatami, Lucia Baratto, Alice C. Fan, Andrei Iagaru
Clinical utility of 68Ga-DOTATOC positron emission tomography/computed tomography for recurrent renal cell carcinoma
Yuji Nakamoto, Takayoshi Ishimori, Yoichi Shimizu, Kohei Sano, Kaori Togashi
Diagnostic performance of 68Ga-PSMA PET/CT for identification of aggressive cribriform morphology in prostate cancer with whole-mount sections
Jie Gao, Chengwei Zhang, Qing Zhang, Yao Fu, Xiaozhi Zhao, Mengxia Chen, Bing Zhang, Danyan Li, Jiong Shi, Feng Wang, Hongqian Guo
Prospective comparison of whole-body MRI and 68Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy
Lino M. Sawicki, Julian Kirchner, Carolin Buddensieck, Christina Antke, Tim Ullrich, Lars Schimmöller, Johannes Boos, Christoph Schleich, Benedikt M. Schaarschmidt, Christian Buchbender, Philipp Heusch, Robert Rabenalt, Peter Albers, Gerald Antoch, Hans-Wilhelm Müller, Hubertus Hautzel
Chemoradiotherapy for locally advanced cervix cancer without aortic lymph node involvement: can we consider metabolic parameters of pretherapeutic FDG-PET/CT for treatment tailoring?
Marie Voglimacci, Erwan Gabiache, Amélie Lusque, Gwenaël Ferron, Anne Ducassou, Denis Querleu, Stéphanie Motton, Elodie Chantalat, Frédéric Courbon, Alejandra Martinez
Adrenal tracer uptake by 18F-FDOPA PET/CT in patients with pheochromocytoma and controls
Walter Noordzij, Andor W. J. M. Glaudemans, Mirte Schaafsma, Anouk N. A. van der Horst-Schrivers, Riemer H. J. A. Slart, André P. van Beek, Michiel N. Kerstens
Dosimetry-based high-activity therapy with 131I-metaiodobenzylguanidine (131I-mIBG) and topotecan for the treatment of high-risk refractory neuroblastoma
Jose Genolla, Trinidad Rodriguez, Pablo Minguez, Ricardo Lopez-Almaraz, Veronica Llorens, Aizpea Echebarria
Pseudoprogression on PSMA PET imaging of a mCRPC patient under anti-PD1 treatment
Larissa Bastos Costa, Marcelo Araujo Queiroz, Felipe de Galiza Barbosa, Rafael Fernandes Nunes, José Flávio Gomes Marin, Carlos Dzik, Carlos Alberto Buchpiguel
One-stop shopping 18F-FDG PET/CT in a patient with vascular type Behçet’s disease
Takashi Norikane, Yuka Yamamoto, Yasukage Takami, Katsuya Mitamura, Hanae Arai-Okuda, Yoshihiro Nishiyama
Correction to: 18F-DOPA PET/CT in brain tumors: impact on multidisciplinary brain tumor board decisions
Olivier Humbert, Véronique Bourg, Lydiane Mondot, Jocelyn Gal, Pierre-Yves Bondiau, Denys Fontaine, Jérôme Barriere, Esma Saada-Bouzid, Marie Paquet, David Chardin, Fabien Almairac, Fanny Vandenbos, Jacques Darcourt